[1] |
Tripathi M, Streutker C J, Marginean E C. Relevance of histology in the diagnosis of reflux esophagitis: Histology of reflux esophagitis[J]. Ann N Y Acad Sci,2018, 1434(1):94-101.
|
[2] |
Savarino E, De Bortoli N, De Cassan C, et al. The natural history of gastro-esophageal reflux disease: a comprehensive review[J]. Dis Esophagus,2017,30(2):1-9.
|
[3] |
He J, Ma X, Zhao Y, et al. A population-based survey of the epidemiology of symptom-defined gastroesophageal reflux disease: the Systematic Investigation of Gastrointestinal Diseases in China[J]. BMC Gastroenterology, 2010, 10(1):94.
|
[4] |
Akyüz F, Mutluay Soyer Ö. How is gastroesophageal reflux disease classified[J]. Turk J Gastroenterol, 2017,28(Suppl 1):S10-S11.
|
[5] |
Ratcliffe E G, Jankowski J A. Gastroesophageal reflux disease and Barrett esophagus: an overview of evidence-based guidelines[J] . Pol Arch Intern Med, 2019, 129(7-8):516-525.
|
[6] |
Kamolz T, Pointier R, Velanovich V. The impact of gastroesophageal reflux disease on quality of life[J]. Surg Endosc, 2003, 17(8):1193-1199.
|
[7] |
Javadi S A H S, Shafikhani A A.Anxiety and depression in patients with gastroesophageal reflux disorder[J]. Electron physician, 2017, 9(8):5107-5112.
|
[8] |
Kimura Y, Kamiya T, Senoo K, et al. Persistent reflux symptoms cause anxiety, depression, and mental health and sleep disorders in gastroesophageal reflux disease patients[J]. J Clin Biochem Nutr, 2016, 59(1):71-77.
|
[9] |
Velanovich V, Karmy-Jones R. Psychiatric disorders affect outcomes of antireflux operations for gastroesophageal reflux disease[J]. Surg Endosc, 2001, 15(2):171-175.
|
[10] |
Bradley L A, Richter J E, Pulliam T J, et al. The relationship between stress and symptoms of gastroesophageal reflux: The influence of psychological factors[J]. Am J Gastroenterol, 1993, 88(1):11-19.
|
[11] |
Velanovich V, Karmy-Jones R. Psychiatric disorders affect outcomes of antireflux operations for gastroesophageal reflux disease[J]. Surg Endosc, 2001, 15(2):171-175.
|
[12] |
Watson D, Chan A, Myers J, et al. Illness behaviour influences the outcome of laparoscopic antireflux surgery[J]. J Am Coll Surg, 1997, 184(1):44-48.
|
[13] |
Coron E, Hatlebakk J G, Galmiche J P. Medical therapy of gastroesophageal reflux disease[J]. Curr Opin Gastroenterol, 2007, 23(4):434-439.
|
[14] |
Miner PB Jr. Review article: physiologic and clinical effects of proton pump inhibitors on non-acidic and acidic gastro-oesophageal reflux [J]. Aliment Pharmacol Ther, 2006, 23(s1):25-32.
|
[15] |
Tougas G, Armstrong D. Efficacy of H2 receptor antagonists in the treatment of gastroesophageal reflux disease and its symptoms[J]. Can J Gastroenterol, 1997, 11 Suppl B:51B-54B.
|
[16] |
Sandhu D S, Fass R. Current trends in the management of gastroesophageal reflux disease[J]. Gut Liver, 2018, 12(1):7-16.
|
[17] |
Preston C, Donnellan C. Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease[M]// Hoboken:John Wiley & Sons, Ltd, 2001.
|
[18] |
Fock K M, Talley N, Goh K L, et al. Asia-Pacific consensus on the management of gastro-oesophageal reflux disease: an update focusing on refractory reflux disease and Barrett\" s oesophagus[J]. Gut, 2016, 65(9):1402-1415.
|
[19] |
Dean B B, Gano A D, Knight K, et al. Effectiveness of proton pump inhibitors in nonerosive reflux disease[J]. Clin Gastroenterol Hepatol, 2004, 2(8):656-664.
|
[20] |
Khan Z, Alastal Y, Khan MA, et al.On-demand therapy with proton pump inhibitors for maintenance treatment of nonerosive reflux disease or mild erosive esophagitis: a systematic review and meta-analysis[J]. Gastroenterol Res Pract, 2018, 2018:1-10.
|
[21] |
Pace F, Porro G B. On-demand PPI therapy in GERD[J]. Curr Treat Options Gastroenterol, 2008, 11(1):35-42.
|
[22] |
Zvyaga T, Chang S Y, Chen C, et al. Evaluation of Six Proton Pump Inhibitors As Inhibitors of Various Human Cytochromes P450: Focus on Cytochrome P450 2C19[J]. Drug Metab Dispos, 2012, 40(9):1698-1711.
|
[23] |
Sugano K. Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date[J]. Therap Adv Gastroenterol, 2018, 11:1756283X1774577.
|
[24] |
Ashida K, Sakurai Y, Nishimura A, et al. Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis[J]. Aliment Pharmacol Ther, 2015, 42(6):685-695.
|
[25] |
Iwakiri K, Umegaki E, Hiramatsu N, et al. Tu1059 a phase 3, randomized, double-blind, multicenter study to evaluate the efficacy and safety of TAK-438 (20 mg once-daily) compared to lansoprazole (30 mg once-daily) in patients with erosive esophagitis[J]. Gastroenterology, 2014, 146(5):S-741.
|
[26] |
Umegaki E, Iwakiri K, Hiramatsu N, et al. Tu1052 a phase 3, randomized, double-blind, multicenter study to evaluate the efficacy and safety of TAK-438 (10 mg or 20 mg once-daily) compared to lansoprazole (15 mg once-daily) in a 24-week maintenance treatment for healed erosive esophagitis[J]. Gastroenterology, 2014, 146(5):S-738.
|
[27] |
Dettmar P W, Sykes J, Little S L, et al. Rapid onset of effect of sodium alginate on gastro-oesophageal reflux compared with ranitidine and omeprazole, and relationship between symptoms and reflux episodes [J].Int J Clin Pract, 2006, 60(3):275-283.
|
[28] |
Pouchain D, Bigard M A, Liard F, et al. Gaviscon vs. omeprazole in symptomatic treatment of moderate gastroesophageal reflux. a direct comparative randomised trial[J]. BMC Gastroenterology, 2012, 12(1):18.
|
[29] |
De Ruigh A, Roman S, Chen J, et al. Gaviscon Double Action Liquid (antacid & alginate) is more effective than antacid in controlling post-prandial oesophageal acid exposure in GERD patients: a double-blind crossover study[J]. Aliment Pharmacol Ther, 2014, 40(5):531-537.
|
[30] |
Rohof W O, Bennink R J, Smout A J, et al. An alginate-antacid formulation localizes to the acid pocket to reduce acid reflux in patients with gastroesophageal reflux disease[J]. Clin Gastroenterol Hepatol, 2013, 11(12):1585-1591.
|
[31] |
Elsborg L, Beck B, Stubgaard M. Effect of sucralfate on gastroesophageal reflux in esophagitis[J]. Hepato-gastroenterology, 1985, 32(4):181-184.
|
[32] |
Hatlebakk J G. Pregnancy and drugs used in gastro-oesophageal reflux[J]. Prescrire Int, 2015, 24(166):297.
|
[33] |
Vãlean S, Petrescu M, C?tinean A, et al. Pill esophagitis[J]. Rom J Gastroenterol, 2005, 14(2):159-163.
|
[34] |
Reddy A N, Budhraja M.Sucralfate therapy for lye-induced esophagitis[J]. Am J Gastroenterol, 1988, 83(1):71-73.
|
[35] |
Fuchs K H, Babic B, Breithaupt W, et al. EAES recommendations for the management of gastroesophageal reflux disease[J]. Surg Endosc, 2014, 28(6):1753-1773.
|
[36] |
Arana A, Johannes C B, McQuay L J, et al.Risk of out-of-hospital sudden cardiac death in users of domperidone, proton pump inhibitors, or metoclopramide: a population-based nested case-control study[J].Drug Saf, 2015, 38(12):1187-1199.
|
[37] |
Lowe R C, Wolfe M M. The pharmacological management of gastroesophageal reflux disease[J]. Minerva Gastroenterol Dietol, 2004, 50(3):227-237.
|
[38] |
Mizuta Y, Shikuwa S, Isomoto H, et al. Recent insights into digestive motility in functional dyspepsia[J].J Gastroenterol, 2006, 41(11):1025-1040.
|
[39] |
Ruth M, Hamelin B, Röhss K, et al. The effect of mosapride, a novel prokinetic, on acid reflux variables in patients with gastro-oesophageal reflux disease[J]. Aliment Pharmacol Ther, 1998, 12(1):35-40.
|
[40] |
Chun B J, Lee D S. The effect of itopride combined with lansoprazole in patients with laryngopharyngeal reflux disease[J]. Eur Arch Otorhinolaryngol, 2013, 270(4):1385-1390.
|
[41] |
Zeng J, Zuo X L, Li Y Q, et al. Tegaserod for dyspepsia and reflux symptoms in patients with chronic constipation: an exploratory open-label study[J]. Eur J Clin Pharmacol, 2007, 63(6):529-536.
|
[42] |
Mertens V, Blondeau K, Pauwels A, et al. Azithromycin reduces gastroesophageal reflux and aspiration in lung transplant recipients[J]. Dig Dis Sci,2009, 54(5):972-979.
|
[43] |
Koek, H G. Effect of the GABAB agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors[J]. Gut, 2003, 52(10):1397-1402.
|
[44] |
Emmitte K A. MGlu5 negative allosteric modulators: A patent review (2010-2012)[J]. Expert Opin Ther Pat, 2013, 23(4):393-408.
|
[45] |
Ostovaneh M R, Saeidi B, Hajifathalian K, et al. Comparing omeprazole with fluoxetine for treatment of patients with heartburn and normal endoscopy who failed once daily proton pump inhibitors: double-blind placebo-controlled trial[J]. Neurogastroenterol Motil, 2014, 26(5):670-678.
|
[46] |
Viazis N, Keyoglou A, Kanellopoulos A K, et al. Selective serotonin reuptake inhibitors for the treatment of hypersensitive esophagus: a randomized, double-blind, placebo-controlled study[J]. Am J Gastroenterol, 2012, 107(11):1662-1667.
|
[47] |
Limsrivilai J, Charatcharoenwitthaya P, Pausawasdi N, et al. Imipramine for treatment of esophageal hypersensitivity and functional heartburn: a randomized placebo-controlled trial[J]. Am J Gastroenterol,2016, 111(2):217-224.
|
[48] |
Tominaga K, Fujiwara Y, Shimoyama Y, et al. Rikkunshito improves symptoms in PPI-refractory GERD patients: a prospective, randomized, multicenter trial in Japan[J]. J Gastroenterol, 2012, 47(3):284-292.
|
[49] |
Wendling M R, Melvin W S, Perry K A. Impact of transoral incisionless fundoplication (TIF) on subjective and objective GERD indices: a systematic review of the published literature[J]. Surg Endosc, 2013, 27(10):3754-3761.
|
[50] |
Fass R, Cahn F, Scotti D J, et al. Systematic review and meta-analysis of controlled and prospective cohort efficacy studies of endoscopic radiofrequency for treatment of gastroesophageal reflux disease[J]. Surg Endosc, 2017, 31(12):4865-4882.
|
[51] |
Liang W T, Wang Z G, Wang F, et al. Long-term outcomes of patients with refractory gastroesophageal reflux disease following a minimally invasive endoscopic procedure: a prospective observational study[J]. BMC Gastroenterol, 2014, 14(1):178.
|
[52] |
Inoue H, Ito H, Ikeda H, et al. Anti-reflux mucosectomy for gastroesophageal reflux disease in the absence of hiatus hernia: A pilot study[J]. Ann Gastroenterol, 2014, 27(4):346-351.
|
[53] |
Robertson A G, Patel R N, Couper G W, et al. Long-term outcomes following laparoscopic anterior and Nissen fundoplication[J]. ANZ J Surg, 2017, 87(4):300-304.
|
[54] |
Omura N, Yano F, Tsuboi K, et al. Surgical results of laparoscopic Toupet fundoplication for gastroesophageal reflux disease with special reference to recurrence[J]. Esophagus,2018,5(4):217-223.
|
[55] |
Yano F, Omura N, Tsuboi K, et al. Laparoscopic Collis gastroplasty and Dor fundoplication for reflux esophagitis complicated by a penetrating ulcer and shortened esophagus: a case report[J]. Surg Laparosc Endosc Percutan Tech,2007, 17(4):322-324.
|
[56] |
Richter J, Kumar A, Lipka S, et al. Efficacy of laparoscopic Nissen fundoplication vs transoral incisionless fundoplication or proton pump inhibitors in patients with gastroesophageal reflux disease: a systematic review and network meta-analysis[J]. Gastroenterology, 2018,154(5):1298-1308.
|
[57] |
Tan G, Yang Z, Wang Z. Meta-analysis of laparoscopic total (Nissen) versus posterior (Toupet) fundoplication for gastro-oesophageal disease based on randomized clinical trials[J]. ANZ J Surg, 2011, 81(4):246-252.
|
[58] |
Roks D J, Koetje J H, Oor J E, et al. Randomized clinical trial of 270° posterior versus 180° anterior partial laparoscopic fundoplication for gastro-oesophageal reflux disease[J]. Br J Surg, 2017, 104(7):843-851.
|
[59] |
Ganz R A. A Modern magnetic implant for gastroesophageal reflux disease (GERD)[J]. Clin Gastroenterol Hepatol, 2016, 15(9):1326-1337.
|
[60] |
Lipham J C, Taiganides P A, Louie B E, et al. Safety analysis of first 1000 patients treated with magnetic sphincter augmentation for gastroesophageal reflux disease[J]. Dis Esophagus, 2015, 28(4):305-311.
|
[61] |
Skubleny D, Switzer N J, Dang J, et al. LINX® magnetic esophageal sphincter augmentation versus Nissen fundoplication for gastroesophageal reflux disease: a systematic review and meta-analysis[J]. Surg Endosc, 2017, 31(8):3078-3084.
|
[62] |
Kappelle W F, Bredenoord A J, Conchillo J M, et al. Electrical stimulation therapy of the lower oesophageal sphincter for refractory gastro-oesophageal reflux disease - interim results of an international multicentre trial[J]. Aliment Pharmacol Ther, 2015, 42(5):614-625.
|
[63] |
Rodríguez L, Rodriguez P, Gómez B, et al. Long-term results of electrical stimulation of the lower esophageal sphincter for the treatment of gastroesophageal reflux disease[J]. Endoscopy, 2013, 45(8):595-604.
|
[64] |
Rodríguez L, Rodriguez P A, Gómez B, et al. Electrical stimulation therapy of the lower esophageal sphincter is successful in treating GERD: long-term 3-year results[J]. Surg Endosc, 2016, 30(7):2666-2672.
|
[65] |
Madalosso C A, Gurski R R, Callegari-Jacques S M, et al. The impact of gastric bypass on gastroesophageal reflux disease in morbidly obese patients[J]. Ann Surg, 2016, 263(1):110.
|
[66] |
Holmberg D, Santoni G, Xie S, et al. Gastric bypass surgery in the treatment of gastro-oesophageal reflux symptoms[J]. Aliment Pharmacol Ther, 2019, 50(2):159-166.
|